Stockscreener 앱 받기
14.75
2.25%
-0.34
시간 외 거래:
14.75
전일 마감가:
$15.09
열려 있는:
$14.82
하루 거래량:
1.10M
Relative Volume:
1.33
시가총액:
$1.30B
수익:
$17.49M
순이익/손실:
$-78.50M
주가수익비율:
-12.29
EPS:
-1.2
순현금흐름:
$-52.85M
1주 성능:
-5.81%
1개월 성능:
-4.78%
6개월 성능:
+47.50%
1년 성능:
+0.00%
1일 변동 폭
$14.41
$14.97
1주일 범위
$14.41
$15.77
52주 변동 폭
$8.26
$16.81
Liquidia Corp Stock (LQDA) Company Profile
명칭
Liquidia Corp
전화
919.328.4400
주소
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
LQDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
14.75 | 1.30B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-16 | 개시 | Raymond James | Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Perform |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2022-09-19 | 재개 | Wedbush | Underperform |
| 2022-09-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2022-07-22 | 개시 | Ladenburg Thalmann | Buy |
| 2022-05-31 | 개시 | BTIG Research | Buy |
| 2022-05-26 | 개시 | BofA Securities | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-05 | 개시 | Wedbush | Outperform |
| 2018-08-20 | 개시 | Jefferies | Buy |
| 2018-08-20 | 개시 | Needham | Buy |
모두보기
Liquidia Corp 주식(LQDA)의 최신 뉴스
Liquidia says its request for Yutrepia final approval undergoes FDA review - MSN
Liquidia stock rises as Yutrepia undergoes FDA review (LQDA) - Seeking Alpha
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder - Investing.com
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA - TipRanks
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder - Yahoo Finance
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
Liquidia Corporation (NASDAQ:LQDA) Q4 2024 Earnings Call Transcript - Insider Monkey
Liquidia (NASDAQ:LQDA) Price Target Raised to $34.00 - Defense World
Earnings To Watch: Liquidia Corp (LQDA) Reports Q4 2024 Result - GuruFocus.com
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects By Investing.com - Investing.com South Africa
What 4 Analyst Ratings Have To Say About Liquidia - Benzinga
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects - Investing.com
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Raymond James maintains strong buy on Liquidia stock, $27 target - Investing.com
H.C. Wainwright maintains Buy on Liquidia stock, $29 target - Investing.com
Raymond James maintains strong buy on Liquidia stock, $27 target By Investing.com - Investing.com UK
Liquidia Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Liquidia Corp (LQDA) - GuruFocus
Earnings call transcript: Liquidia Technologies Q4 2024 misses revenue forecast - Investing.com
Liquidia Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Liquidia Corp Reports Annual EPS of -$1.66 and Revenue of $14.0 Million, Missing Estimates - GuruFocus.com
Liquidia Corp SEC 10-K Report - TradingView
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update - TradingView
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million - The Manila Times
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable? - Simply Wall St
Commit To Buy Liquidia At $7.50, Earn 11.3% Using Options - Nasdaq
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 - The Manila Times
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 - GlobeNewswire Inc.
Rare Disease Biotech Liquidia Schedules Critical 2024 Financial Review - StockTitan
Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA) - GuruFocus.com
Liquidia’s chief commercial officer sells shares worth $9,146 By Investing.com - Investing.com Canada
Liquidia’s chief commercial officer sells shares worth $9,146 - Investing.com India
Liquidia Corp CFO Michael Kaseta sells shares worth $13,503 - Investing.com
Liquidia Corp Executives Sell Shares - TradingView
FDA Was Right to Delay Approving Liquidia's Yutrepia, Judge Says - Bloomberg Law
Liquidia Corp loses FDA lawsuit; Tyvaso DPI exclusivity stands - Investing.com
Liquidia Challenge To UTC's Tyvaso Exclusivity Fails - Law360
Bleakley Financial Group LLC Lowers Stock Position in Liquidia Co. (NASDAQ:LQDA) - Defense World
The Attractiveness of Investing In Liquidia Corp (LQDA) is Growing - Knox Daily
Analysts Set Liquidia Co. (NASDAQ:LQDA) Target Price at $25.38 - Armenian Reporter
Liquidia Co. (NASDAQ:LQDA) Receives $25.38 Average Price Target from Brokerages - MarketBeat
Liquidia Corp's chief business officer sells $6,319 in stock - MSN
Life Sciences Group Of The Year: Cooley - Law360
Stock Performance Spotlight: Liquidia Corp (LQDA) Ends the Day at 15.74, Up by 3.89 - The Dwinnex
Liquidia Corp.: We Have Exposure To The Upside Now - Seeking Alpha
Liquidia Corp (LQDA) stock on the rise: An overview - US Post News
Arquitos Capital Management Q4 2024 Commentary - Seeking Alpha
This trade activity should not be overlooked: Liquidia Corp (LQDA) - SETE News
Liquidia Corp [LQDA] Investment Appeal on the Rise - Knox Daily
Liquidia Corporation's Long-Running Saga Is Coming To An End (NASDAQ:LQDA) - Seeking Alpha
Liquidia Corp (LQDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):